問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

林棟樑Lin, Tung-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

48Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林棟樑

List

110Cases

2017-12-01 - 2020-12-31

Phase III

GRAVITAS-301： A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

  • Condition/Disease

    Acute Graft Versus Host Disease

  • Test Drug

    Itacitinib

Participate Sites
4Sites

Terminated3Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2018-11-01 - 2021-04-23

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

  • Condition/Disease

    Adult Ulcerative Colitis (UC); Adult Crohn′s Disease (CD); acute graft-versus-host disease (aGvHD)

  • Test Drug

    Entyvio (Vedolizumab IV or MLN0002 IV) 300 mg/vial (60 mg/mL)

Participate Sites
7Sites

Terminated7Sites

2014-07-01 - 2023-10-25

Phase III

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated4Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2012-06-01 - 2018-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-02-01 - 2021-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-05-10 - 2022-09-26

Phase II

A Phase 1/2 Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide with and without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

  • Condition/Disease

    Relapsed/Refractory Multiple Myeloma

  • Test Drug

    AMG701

Participate Sites
3Sites

Terminated3Sites

2013-09-01 - 2016-06-21

Phase III

A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Carfilzomib

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2017-01-13 - 2023-12-31

Phase III

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    ASP2215

Participate Sites
7Sites

Terminated5Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

1 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB